AAP
ABUS icon

Arax Advisory Partners’s Arbutus Biopharma ABUS Stock Holding History

Arax Advisory Partners’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.06K Buy
1,471
+1,309
+808% +$5.75K ﹤0.01% 4483
2026
Q1 		$729 Sell
162
-1,071
-87% -$4.68K ﹤0.01% 3356
2025
Q4 		$5.93K Buy
+1,233
New +$5.54K ﹤0.01% 2754
2025
Q1 		– Sell
-1,206
Closed -$3.94K – 2660
2024
Q4 		$3.94K Hold
1,206
– – ﹤0.01% 1825
2024
Q3 		$4.64K Hold
1,206
– – ﹤0.01% 1745
2024
Q2 		$3.73K Buy
+1,206
New +$3.62K ﹤0.01% 1717

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Arax Advisory Partners's ABUS Position: Q2 2026 in Review

Arax Advisory Partners increased its Arbutus Biopharma (ABUS) stake by 808% in Q2 2026, buying an estimated $5.75K and bringing the position to 1,471 shares worth $7.06K. The position accounts for ﹤0.01% of the portfolio, ranked #4483.

Arax Advisory Partners first reported a position in ABUS in Q2 2024 and has held it in 6 quarters since. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • Arax Advisory Partners held 1,471 shares of Arbutus Biopharma worth $7.06K as of Q2 2026.
  • Arax Advisory Partners bought 1,309 Arbutus Biopharma shares in Q2 2026, an estimated $5.75K.
  • Arbutus Biopharma made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4483 holding.
  • Arax Advisory Partners first reported a position in Arbutus Biopharma in Q2 2024 and has held it in 6 quarters since.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.